Edition:
United States

Aratana Therapeutics Inc (PETX.OQ)

PETX.OQ on NASDAQ Stock Exchange Global Market

3.41USD
24 Apr 2019
Change (% chg)

$0.00 (+0.00%)
Prev Close
$3.41
Open
$3.45
Day's High
$3.51
Day's Low
$3.40
Volume
37,388
Avg. Vol
105,621
52-wk High
$7.16
52-wk Low
$3.31

Latest Key Developments (Source: Significant Developments)

Aratana Therapeutics posts Q4 Loss Per Share of $0.18
Tuesday, 12 Mar 2019 04:05pm EDT 

March 12 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2018 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.18.Q4 REVENUE $4.9 MILLION VERSUS $10.5 MILLION.ARATANA THERAPEUTICS - AS OF DECEMBER 31, 2018, HAD ABOUT $43.0 MILLION IN CASH, CASH EQUIVALENTS, RESTRICTED CASH & SHORT-TERM INVESTMENTS ON DEBT-FREE BASIS.IN 2019, EXPECTS A NET DECREASE OF CASH OF APPROXIMATELY $20.0 MILLION TO BE USED TO SUPPORT CURRENT ACTIVITIES.ARATANA THERAPEUTICS - BELIEVE CURRENT CASH, CASH EQUIVALENTS, RESTRICTED CASH & SHORT-TERM INVESTMENTS SUFFICIENT TO FUND TILL Q1 2020.Q4 EARNINGS PER SHARE VIEW $-0.14, REVENUE VIEW $6.2 MILLION -- REFINITIV IBES DATA.  Full Article

Aratana Therapeutics - Repaid in full outstanding indebtedness, terminated all commitments under its loan and security agreement, dated Oct 16, 2015
Friday, 28 Dec 2018 08:05am EST 

Dec 28 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS - REPAID IN FULL OUTSTANDING INDEBTEDNESS, TERMINATED ALL COMMITMENTS UNDER ITS LOAN AND SECURITY AGREEMENT, DATED OCT 16, 2015.ARATANA THERAPEUTICS INC - CO DID NOT INCUR ANY EARLY TERMINATION PENALTIES AS A RESULT OF REPAYMENT OF INDEBTEDNESS OR TERMINATION OF LOAN AGREEMENT.ARATANA THERAPEUTICS INC - PAYMENT TO LENDERS UNDER LOAN AGREEMENT WAS APPROXIMATELY $20.6 MILLION.  Full Article

Aratana Therapeutics Reports Q3 Earnings Per Share $0.19
Thursday, 1 Nov 2018 04:05pm EDT 

Nov 1 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS REPORTS THIRD QUARTER 2018 FINANCIAL RESULTS.Q3 EARNINGS PER SHARE $0.19.QTRLY TOTAL REVENUES $21.6 MILLION VERSUS $6.2 MILLION.  Full Article

Aratana Therapeutics Says On July 5, Co, Pacira Pharmaceuticals Entered Amendment, Restatement Of Exclusive License, Development, Commercialization Deal
Monday, 9 Jul 2018 04:23pm EDT 

July 9 (Reuters) - Pacira Pharmaceuticals Inc ::ARATANA THERAPEUTICS - ON JULY 5, CO, PACIRA PHARMACEUTICALS ENTERED AMENDMENT, RESTATEMENT OF EXCLUSIVE LICENSE, DEVELOPMENT, COMMERCIALIZATION DEAL.ARATANA THERAPEUTICS SAYS AMENDED AGREEMENTS PRIMARILY RELATE TO PROVIDING ACCESS AND SUPPLY OF A 10ML VIAL SIZE BY PACIRA TO CO FOR NOCITA(REG).  Full Article

Engaged Capital Reports 5.2 Pct Stake In Aratana Therapeutics Inc, As Of April 4, 2018 SEC Filing
Thursday, 5 Apr 2018 09:12am EDT 

April 5 (Reuters) - Aratana Therapeutics Inc ::SEC FILING.ENGAGED CAPITAL LLC SAYS PURCHASED ARATANA THERAPEUTICS' SHARES BASED ON BELIEF THAT THE SHARES, WHEN PURCHASED, WERE UNDERVALUED.ENGAGED CAPITAL LLC SAYS HAS ENGAGED, TO CONTINUE TO ENGAGE, IN COMMUNICATIONS WITH ARATANA THERAPEUTICS BOARD FOR MEANS TO CREATE STOCKHOLDER VALUE.ON MARCH 23, DELIVERED LETTER TO ARATANA THERAPEUTICS NOMINATING CRAIG BARBAROSH, ERIC ENDE, LOWELL ROBINSON FOR ELECTION TO BOARD ‍​.  Full Article

Aratana Therapeutics Reports Q4 Loss Per Share $0.37
Tuesday, 13 Mar 2018 04:05pm EDT 

March 13 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS.Q4 LOSS PER SHARE $0.37.Q4 REVENUE $10.4 MILLION VERSUS $292,000.Q4 2017 NET LOSS INCLUDED $7.4 MILLION OF IMPAIRMENT CHARGES FOR INTANGIBLE ASSETS.EXPECTS ABOUT $35.0 MILLION OF CASH TO BE USED FOR ON-GOING OPERATIONS IN 2018.Q4 EARNINGS PER SHARE VIEW $-0.21, REVENUE VIEW $6.8 MILLION -- THOMSON REUTERS I/B/E/S.  Full Article

Aratana Therapeutics Expands Therapeutic Candidate Pipeline
Thursday, 1 Mar 2018 08:30am EST 

March 1 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS EXPANDS THERAPEUTIC CANDIDATE PIPELINE.ARATANA THERAPEUTICS INC - ANNOUNCED AN ANIMAL HEALTH RESEARCH AND DEVELOPMENT COLLABORATION WITH ASKAT INC.ARATANA THERAPEUTICS INC - LICENSED EXCLUSIVE, WORLDWIDE RIGHTS TO DEVELOP AND COMMERCIALIZE AT-019, KNOWN AS AAT-008 BY ASKAT.ARATANA THERAPEUTICS INC - AT-019 LICENSE AGREEMENT INCLUDES AN UPFRONT PAYMENT OF $0.5 MILLION; MILESTONE PAYMENTS OF UP TO $15.5 MILLION.  Full Article

Aratana Therapeutics Granted Conditional License For A Canine Osteosarcoma Therapeutic
Wednesday, 20 Dec 2017 08:05am EST 

Dec 20 (Reuters) - Advaxis Inc ::ARATANA THERAPEUTICS GRANTED CONDITIONAL LICENSE FOR A CANINE OSTEOSARCOMA THERAPEUTIC.ARATANA THERAPEUTICS-U.S. DEPARTMENT OF AGRICULTURE CENTER FOR VETERINARY BIOLOGICS GRANTED CONDITIONAL LICENSE​ FOR CANINE OSTEOSARCOMA VACCINE,AT-014.  Full Article

Aratana Therapeutics Says Study Did Not Achieve Protocol-Defined Efficacy Success Criteria
Friday, 15 Dec 2017 04:15pm EST 

Dec 15 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS ANNOUNCES STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS INC - ARATANA'S LICENSE PARTNER RESPONSIBLE FOR DEVELOPMENT OF AT-016 SHARED RESULTS OF A PIVOTAL STUDY.ARATANA THERAPEUTICS - RECEIVED TOP-LINE PIVOTAL FIELD EFFECTIVENESS STUDY RESULTS FOR AT-016.ARATANA THERAPEUTICS - PARTNER RESPONSIBLE FOR AT-016 SHARED RESULTS OF PIVOTAL STUDY, WHICH DID NOT ACHIEVE PROTOCOL-DEFINED EFFICACY SUCCESS CRITERIA.ARATANA THERAPEUTICS INC - AS PART OF CO'S EXCLUSIVE COMMERCIAL LICENSE FOR DOGS WITH OSTEOARTHRITIS IN U.S., CO FUNDED CLINICAL STUDY & OTHER WORK.ARATANA THERAPEUTICS - CO ANTICIPATES AFTER PARTNER EVALUATED STUDY RESULTS, PARTIES TO DETERMINE IF COLLABORATION TO BRING THERAPEUTIC TO MARKET TO CONTINUE.  Full Article

Aratana Therapeutics Announces Proposed Public Offering
Monday, 27 Nov 2017 04:10pm EST 

Nov 27 (Reuters) - Aratana Therapeutics Inc ::ARATANA THERAPEUTICS, INC. ANNOUNCES PROPOSED PUBLIC OFFERING.ARATANA THERAPEUTICS INC - ‍COMMENCING AN UNDERWRITTEN REGISTERED PUBLIC OFFERING OF $35 MILLION OF SHARES OF ITS COMMON STOCK​.ARATANA THERAPEUTICS INC - ‍ALL OF SHARES ARE BEING OFFERED BY ARATANA THERAPEUTICS​.  Full Article